This experiment examined a peptide around a vascular procedure. It was not a general trial of elamipretide for chronic kidney disease. Primary report
Study snapshot
Fourteen patients undergoing revascularization for severe atherosclerotic renal-artery stenosis received elamipretide or placebo. The investigators reported patterns consistent with less immediate postprocedural hypoxia and favorable later perfusion and kidney-function findings. Imaging and laboratory measurements were collected at different intervals around the procedure. Primary report
Our appraisal: distinguish procedure recovery from added drug effect
Because both groups underwent a major intervention, improvement over time cannot automatically be assigned to the adjunctive drug. The relevant question is how the randomized groups differed, with uncertainty around that difference.
The abstract's within-group significance statements should not be read as a substitute for a direct between-group comparison. One group reaching a significance threshold while another does not is not itself evidence that their changes differ significantly.
Timing and measurement also define the claim. An imaging-derived hypoxia measure shortly after intervention and estimated filtration months later describe different processes. They can support a biological narrative without proving every causal link in that narrative.
The very small groups make baseline balance and individual influence important. Review should examine participant allocation, concurrent treatment, imaging reproducibility, contrast exposure, and all adverse events. The study can motivate a larger procedural trial, but it does not establish prevention of dialysis, durable kidney protection across diseases, or a nonprocedural treatment protocol.
Frequently asked questions
Did all participants undergo revascularization?
The study concerned patients scheduled for that procedure.
Was elamipretide studied as an adjunct?
Yes.
Can a pre-post improvement isolate the drug's effect?
No. The comparison with the other randomized group is needed.
Do different within-group P values prove different effects?
No.
Were imaging and filtration the same endpoint?
No.
Can the findings establish general kidney-disease treatment?
No. The population and procedural context are narrow.
What needs confirmation?
The size, precision, durability, and safety of the adjunctive effect in a larger suitable study.